amgen inc (AMGN:NASDAQ GS)

Executive Profile*

Background*

Mr. Mark A. McCamish, M.D., Ph.D. serves as the Global Head of Biopharmaceutical Development at Sandoz International, a Division of Novartis. Dr. McCamish served as Chief Medical Officer and Senior Vice President of Abbott Biotherapeutics Corp. (Also known as Facet Biotech Corporation). since December 2008. He served as a Senior Vice President and Chief Medical officer of PDL BioPharma Inc., from February 21, 2007 to December 2008. He has over 25 years of experience ... in corporate management, clinical and pharmaceutical research, and academics. Dr. McCamish served as Vice President of Clinical Development at Perlegen Sciences Inc. from August 2003 to February 2007 and served as its Chief Medical Officer from September 2003 to February 2007. From January 1998 to September 2003, he served at Amgen, Inc., as a Global Development Leader and was responsible for the clinical development of Amgen's Aranesp® product in new indications. He serves as a Director of Trigemina, Inc. He served as Medical Director of Abbott Laboratories. From 1990 to 1997, he served as a Director at Abbott Laboratories. Dr. McCamish also served as a Member of Amgen's International Clinical Oversight Group responsible for approval of all clinical research protocols, clinical study reports and FDA/Regulatory submissions. Dr. McCamish has held positions as a professor of Surgery at Michigan State University from 1980-1983, Internal Medicine at the University of California at Davis from 1987-1990, and Endocrinology at The Ohio State University from 1990-1997. He is a Board Certified in Internal Medicine and Nutrition & Metabolism. Dr. McCamish holds a B.S. in Physical Education and an M.S. in Ergonomics from the University of California at Santa Barbara, a Ph.D. in Human Nutrition from The Pennsylvania State University and an M.D. from the University of California at Los Angeles.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
AMGN:US	$105.91 USD	+0.29

COMPETITOR COMPENSATION